Figure 2 Quantitative polymerase chain reaction (qPCR) results measuring SARS-CoV-2 genetic material in response to treatment with R327 in Syrian golden hamsters. SYDNEY, Australia, Oct. 18, 2022 ...
Recce has successfully dosed half of target patients with RECCE 327 in its Phase 2 trial for Acute Bacterial Skin Infections. Don't miss out on the headlines from Stockhead. Followed categories will ...
SYDNEY, Australia, July 16, 2020 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE) (Company), the company developing new classes of synthetic anti-infectives, today announced it has entered ...
Phase I/II trial agreement with Fiona Stanley Hospital (Burns Unit) in Perth Western Australia Study led by world leading burn treatment specialists Study will assess safety and efficacy of RECCE ® ...
SYDNEY, Australia, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE) (Company), the Company developing new classes of synthetic anti-infectives, today announced results of RECCE ® ...
Clinical study review board remains on track to review the data in mid-October with interim results to follow Special Report: Recce Pharmaceuticals has announced the successful dosing of half of its ...
Recce has successfully dosed half of target patients with RECCE 327 in its Phase 2 trial for Acute Bacterial Skin Infections. Clinical study review board remains on track to review the data in ...
Recce has successfully dosed half of target patients with RECCE 327 in its Phase 2 trial for Acute Bacterial Skin Infections. Special Report: Recce Pharmaceuticals has announced the successful dosing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback